Therapeutic hepatitis B vaccine employing DNA prime - MVA boost scheme requires additional priming with recombinant HBsAg to elicit an adequate antibody response.
Saved in:
| Title: | Therapeutic hepatitis B vaccine employing DNA prime - MVA boost scheme requires additional priming with recombinant HBsAg to elicit an adequate antibody response. |
|---|---|
| Authors: | Kerth HA; Institute of Virology, School of Medicine and Health, Technical University of Munich/Helmholtz Munich, Munich, Germany.; German Center for Infection Research (DZIF), Munich Partner Site, Munich, Germany., Kächele M; Institute of Virology, School of Medicine and Health, Technical University of Munich/Helmholtz Munich, Munich, Germany., Müller N; Institute of Virology, School of Medicine and Health, Technical University of Munich/Helmholtz Munich, Munich, Germany., Singh S; Institute of Virology, School of Medicine and Health, Technical University of Munich/Helmholtz Munich, Munich, Germany., Tulessin M; Institute of Pathology, School of Medicine and Health, Technical University of Munich, Munich, Germany., Sacherl J; Institute of Virology, School of Medicine and Health, Technical University of Munich/Helmholtz Munich, Munich, Germany., Ates Öz E; Institute of Virology, School of Medicine and Health, Technical University of Munich/Helmholtz Munich, Munich, Germany.; German Center for Infection Research (DZIF), Munich Partner Site, Munich, Germany., Su J; Institute of Virology, School of Medicine and Health, Technical University of Munich/Helmholtz Munich, Munich, Germany.; German Center for Infection Research (DZIF), Munich Partner Site, Munich, Germany., Bester R; Institute of Virology, School of Medicine and Health, Technical University of Munich/Helmholtz Munich, Munich, Germany., Miko S; Institute of Virology, School of Medicine and Health, Technical University of Munich/Helmholtz Munich, Munich, Germany., Steiger K; Institute of Pathology, School of Medicine and Health, Technical University of Munich, Munich, Germany., Mogler C; Institute of Pathology, School of Medicine and Health, Technical University of Munich, Munich, Germany., Busch DH; German Center for Infection Research (DZIF), Munich Partner Site, Munich, Germany.; Institute for Medical Microbiology, Immunology and Hygiene, School of Medicine and Health, Technical University of Munich, Munich, Germany., Wettengel JM; Institute of Virology, School of Medicine and Health, Technical University of Munich/Helmholtz Munich, Munich, Germany.; German Center for Infection Research (DZIF), Munich Partner Site, Munich, Germany., Protzer U; Institute of Virology, School of Medicine and Health, Technical University of Munich/Helmholtz Munich, Munich, Germany.; German Center for Infection Research (DZIF), Munich Partner Site, Munich, Germany., Kosinska AD; Institute of Virology, School of Medicine and Health, Technical University of Munich/Helmholtz Munich, Munich, Germany.; German Center for Infection Research (DZIF), Munich Partner Site, Munich, Germany. |
| Source: | Frontiers in immunology [Front Immunol] 2026 Mar 12; Vol. 17, pp. 1771887. Date of Electronic Publication: 2026 Mar 12 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2026.1771887 |
